SEC Form 4						
FORM 4	UNITED STAT	OMB APPROVAL				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).		TOF CHANGES IN BENEFICIAL OWNE	ERSHIP	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person* COSTA SANTO J (Last) (First) (Middle) C/O AQUESTIVE THERAPEUTICS, INC.		or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Aquestive Therapeutics, Inc.</u> [ AQST ] 3. Date of Earliest Transaction (Month/Day/Year) 06/15/2021	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)			
30 TECHNOLOGY DRIVE (Street) WARREN NJ	07059	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	ansaction Disposed Of ode (Instr. 5)		isposed Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock								17,327	D		

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 6. Date Exercisable and Expiration Date (Month/Day/Year) 1. Title of Derivative 3. Transaction Date 3A. Deemed Execution Date 8. Price of Derivative 11. Nature of Indirect 2. Conversion 5. Number 9. Number of 10. Ownership Form: Transaction of derivative or Exercise Price of Derivative (Month/Day/Year) Derivative Security (Instr. 3) Code (Instr. 8) Security (Instr. 5) if anv Securities Beneficial Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) Direct (D) or Indirect (I) (Instr. 4) Ownership (Instr. 4) (Month/Day/Year) Security Amount or Number Date Expiration Date of Shares Code v (A) (D) Exercisable Title Stock Option \$4.04 06/15/2021 20,000 06/15/2022<sup>(1)</sup> 06/15/2031 Common 20,000 20,000 A \$<mark>0</mark> D (Right to Purchase Stock

## Explanation of Responses:

1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Mr. Costa's continuous service with the Issuer from the grant date through the applicable vesting date.

## Remarks:

(City)

(State)

(Zip) . .

## /s/ Lori Braender, as Attorney-06/17/2021 In-Fact

...

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.